$28.05
-0.90 (-3.11%)
Open$28.01
Previous Close$28.95
Day High$28.63
Day Low$27.75
52W High$37.50
52W Low$16.50
Volume—
Avg Volume113.6K
Market Cap100.62M
P/E Ratio—
EPS$-20.59
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
-2.7% upside
Current
$28.05
$28.05
Target
$27.28
$27.28
$18.57
$27.28 avg
$35.01
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 32.04M | 12.22M | 12.16M |
| Net Income | -82,633,534 | 1.67M | 1.59M |
| Profit Margin | -257.9% | 13.7% | 13.1% |
| EBITDA | -59,437,501 | 2.79M | 3.00M |
| Free Cash Flow | — | 1.30M | 1.27M |
| Rev Growth | — | +12.4% | +20.7% |
| Debt/Equity | — | 0.63 | 0.63 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |